Anti-vascular endothelial growth factor for neovascular agerelated macular degeneration

Keyphrases

• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 100%
• Bevacizumab 84%
• Ranibizumab 84%
• Confidence Interval 61%
• Visual Acuity 61%
• Pegaptanib 53%
• Risk Ratio 38%
• Randomized Controlled Trial 30%
• Intravitreous Injection 30%
• Age-related Macular Degeneration 23%
• Control Method 23%
• Vision Loss 23%
• Visual Acuity Outcome 15%
• Risk of Bias 15%
• Cochrane 15%
• Ovid 15%
• Photodynamic Therapy 15%
• Retinal Thickness 15%
• Myopic Choroidal Neovascularization (mCNV) 15%
• Number of Trials 15%
• Anti-vascular Endothelial Growth Factor Therapy 15%
• Clinically Significant 7%
• Low Risk 7%
• South America 7%
• Control Intervention 7%
• Relative Effect 7%
• Endophthalmitis 7%
• Between-group 7%
• Quality of Life 7%
• Economic Outcomes 7%
• High Incidence 7%
• Clinical Trials 7%
• Ocular Inflammation 7%
• Literature Database 7%
• Methodological Procedures 7%
• Science Literature 7%
• MEDLINE 7%
• Selection Criteria 7%
• Latin American 7%
• Caribbean 7%
• Embase 7%
• Electronic Search 7%
• International Clinical Trials Registry Platform (ICTRP) 7%
• Visual Function 7%
• Search Methods 7%
• Health Sciences 7%
• Ongoing Trials 7%
• North America 7%
• Increased Intraocular Pressure 7%
• Most Common Cause 7%
• Developing World 7%
• Intravitreal Injection 7%
• Adverse Effects 7%
• Safety Outcomes 7%
• Review Authors 7%
• Systemic Effects 7%
• Number of Participants 7%
• Cochrane Review 7%
• World Health Organization 7%
• Extracted Data 7%
• Asia 7%
• Meaningful Difference 7%
• Systemic Side Effects 7%
• Pharmaceutical Companies 7%
• Combination Therapy 7%
• Cochrane Central Register of Controlled Trials 7%
• Vision Threatening 7%
• Dosing Regimen 7%
• Number of Events 7%
• Ocular Side Effects 7%
• Quality of Life Outcomes 7%
• Measurement Error 7%
• Certainty of Evidence 7%
• Anti-VEGF Therapy 7%
• Trial Participants 7%
• Sham Treatment 7%
• Ocular Effects 7%
• Abnormal Blood Vessels 7%
• South Europe 7%
• Measurement Range 7%
• Trial Sample Size 7%
• South Australia 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Vasculotropin 100%
• Macular Degeneration 100%
• Bevacizumab 68%
• Ranibizumab 68%
• Pegaptanib 43%
• Randomized Controlled Trial 25%
• Adverse Event 18%
• Age Related Macular Degeneration 18%
• Visual Impairment 18%
• Clinical Trial 12%
• Wet Macular Degeneration 12%
• Subretinal Neovascularization 12%
• Photodynamic Therapy 12%
• Intravitreal Administration 6%
• Endophthalmitis 6%
• Combination Therapy 6%
• Eye Inflammation 6%
• Placebo 6%

Neuroscience

• Vascular Endothelial Growth Factor 100%
• Macular Degeneration 100%
• Bevacizumab 68%
• Ranibizumab 68%
• Pegaptanib 43%
• Age-Related Macular Degeneration 31%
• Randomized Controlled Trial 25%
• Choroidal Neovascularization 12%
• Intraocular Pressure 6%
• Endophthalmitis 6%
• Adverse Effect 6%